Probiotics and Prebiotics: Effects on Diarrhea

Bioactive Foods in Promoting Health

Volumn , Issue , 2010, Pages 205-227

  de Vrese, Michael ^a   Offick, B ^a  

^a FEDERAL RESEARCH INSTITUTE OF NUTRITION AND FOOD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80155127594     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374938-3.00014-1     Document Type: Chapter

References (201)

1. Bottazzi V. Food and feed production with microorganisms. Biotechnology 1983, 5:315-363.
2. Carre C. Ueber Antagonisten unter den Bacterien. Correspondenz-Blatt fuer Schweizer Aerzte 1887, 17:385-392.
3. Tissier H. Traitement des infections intestinales par la méthode de la flore bactérienne de l'intestin. Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales 1906, 60:359-361.
4. Metchnikoff, E. (1907). Lactic acid as inhibiting intestinal putrefaction. In: The prolongation of life: optimistic studies. London: W. Heinemann (pp. 161-183). 4.
5. Kollath W. The increase of the diseases of civilization and their prevention. Munchener Medizinische Wochenschrift 1953, 95:1260-1262.
6. Lilly D.M., Stillwell R.H. Probiotics. Growth promoting factors produced by micro-organisms. Science 1965, 147:747-748.
7. Schrezenmeir J., de Vrese M. Probiotics, prebiotics, and synbiotics: approaching a definition. American Journal of Clinical Nutrition 2001, 73:361-364.
8. Gibson G.R., Roberfroid M.B. Dietary modulation of the colonic microbiota: introducing the concept of prebiotics. Journal of Nutrition 1995, 125:1401-1412.
9. Institute of Food Technologists, Functional Foods: Opportunities and Challenges (2005). Available at (Accessed and printed on April 1, 2009). http://www.members.ift.org/IFT/Research/IFTExpertReports/functionalfoods_report.htm.
10. Marteau P., de Vrese M., Cellier C., Schrezenmeir J. Protection from gastrointestinal diseases using probiotics. American Journal of Clinical Nutrition 2001, 73:430S-436S.
11. de Vrese M., Marteau P.R. Probiotics and prebiotics: effects on diarrhea. Journal of Nutrition 2007, 137:803S-811S.
12. Sazawal S., Hiremath G., Dhingra U., et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infectious Diseases 2006, 6:374-382.
13. WHO. Available at (Accessed and printed on April 1, 2009). http://www.who.int/topics/diarrhoea/en/.
14. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
15. Mcfarlane S., Macfarlane G.T. Regulation of short-chain fatty acid production. Proceedings of the Nutrition Society 2003, 62:67-72.
16. Wong J.M., de Souza R., Kendall C.W., et al. Colonic health: fermentation and short chain fatty acids. Journal of Clinical Gastroenterology 2006, 40:235-243.
17. Hijova E., Chmelarova A. Short chain fatty acids and colonic health. Bratisl Lek Listy 2007, 108:354-358.
18. Cherbut C., Ferrier L., Rozé C., et al. Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. American Journal of Physiology 1998, 275:1415-1422.
19. Guarner F., Malagelada J.R. Gut flora in health and disease. Lancet 2003, 361:512-519.
20. Bergman E. Energy contribution of volatile fatty acids from the gastrointestinal tract in various species. Physiological Reviews 1990, 70:567-590.
21. Wachtershauser A., Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. European Journal of Nutrition 2000, 39:164-171.
22. Vernia P., Annese V., Bresci G., et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. European Journal of Clinical Investigation 2003, 33:244-248.
23. Yan F., Cao H., Cover T.L., et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007, 132:562-575.
24. Ukena S.N., Singh A., Dringenberg U., et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PloS ONE 2007, 2:e1308.
25. Zareie M., Johnson-Henry K., Jury J., et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006, 55:1553-1560.
26. Steinman R.M. Some interfaces of dendritic cell biology. APMIS 2003, 111:675-697.
27. Yang E.V., Glaser R. Stress-induced immunomodulation: impact on immune defenses against infectious disease. Biomedicine & Pharmacotherapy 2000, 54:245-250.
28. Ginaldi L., De Martinis M., Monti D., Franceschi C. The immune system in the elderly: activation-induced and damage-induced apoptosis. Immunologic Research 2004, 30:81-94.
29. Gleeson M. Immune function in sport and exercise. Journal of Applied Physiology 2007, 103:693-699.
30. Wolowczuk, I., Verwaerde, C., Viltart, O., et al. (2008). Feeding our immune system: impact on metabolism. Clin Dev Immunol, Article 639803.
31. Saavedra J.M., Baumann N.A., Oung I., et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet 1994, 34:1046-1049.
32. Isolauri E., Joensuu J., Suolamalainen H., et al. Improved immunogenecity of oral DxRRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995, 13:310-312.
33. Majamaa H., Isolauri E., Saxelin M., Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. Journal of Pediatric Gastroenterology Nutrition 1995, 20:333-338.
34. Shornikova A.V., Casas I.A., Isolauri E., Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. Journal of Pediatric Gastroenterology Nutrition 1997, 24:399-404.
35. Buydens P., Debeuckelaere S. Efficacy of SF68 in the treatment of acute diarrhea. A placebo controlled trial. Scandinavian Journal of Gastroenterology 1996, 31:887-891.
36. Guandalini S., Pensabene L., Zikri M.A., et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. Journal of Pediatric Gastroenterology Nutrition 2000, 30:54-60.
37. Dubey A.P., Rajeshwari K., Chakravarty A., Famularo G. Use of VSL#3 in the treatment of rotavirus diarrhea in children: preliminary results. Journal of Clinical Gastroenterology 2008, 42(Suppl. 3 Pt. 1):S126-S129.
38. Allan, S. J., Okoko, B., Martinez, E., et al. (2004). Probiotics for treating infectious diarrhoea CD003048. Cochrane Database Syst Rev(2).
39. Huang J.S., Bousvaros A., Lee J.W., et al. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Digestive Diseases and Sciences 2002, 47:2625-2634.
40. Guandalini S. Probiotics for children with diarrhea: an update. Journal of Clinical Gastroenterology 2008, 42(Suppl. 2):S53-S57.
41. Van Niel C.W., Feudtner C., Garrison M.M., Christakis D.A. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002, 109:678-684.
42. Szajewska H., Skórka A., Ruszczyński M., Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Alimentary Pharmacology & Therapeutic 2007, 25(8):871-881.
43. Krammer H.J., Kamper H., von Bunau R., et al. Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3807 Patients. Zeitschrift Fur Gastroenterologie 2006, 44:651-656.
44. Henker J., Laass M., Blokhin B.M., et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhea in infants and toddlers. European Journal of Pediatrics 2007, 166:311-318.
45. Gedek B.R. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 1999, 42(4):261-264.
46. Castagliuolo I., Riegler M.F., Valenick L., et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infection and Immunity 1999, 67(1):302-307.
47. Dahan S., Dalmasso G., Imbert V., et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infection and Immunity 2003, 71(2):766-773.
48. Thomas S., Przesdzing I., Metzke D., et al. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clinical and Experimental Immunology 2009, 155:78.
49. Kurugöl Z., Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Peadiatrica 2005, 94:44-47.
50. Villarruel G., Rubio D.M., Lopez F., et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatrica 2007, 96:538-541.
51. Htwe K., Yee K.S., Tin M., Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. American Journal of Tropical Medicine and Hygiene 2008, 78:214-216.
52. Billoo A.G., Memon M.A., Khaskheli S.A., et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World Journal of Gastroenterology 2006, 12:4557-4560.
53. McFarland L., Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microbial Ecology in Health and Disease 1993, 6:157-171.
54. Szajewska H., Skórka A., Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Alimentary Pharmacology & Therapeutic 2007, 25(3):257-264.
55. Salazar-Lindo E., Miranda-Langschwager P., Campos-Sanchez M., et al. Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial. BMC Pediatrics 2004, 4:18.
56. Costa-Ribeiro H., Ribeiro T.C., Mattos A.P., et al. Limitations of probiotic therapy in acute, severe dehydrating diarrhea. Journal of Pediatric Gastroenterology Nutrition 2003, 36:112-115.
57. Basu S., Chatterjee M., Ganguly S., Chandra P.K. Efficacy of Lactobacillus rhamnosus GG in persistent diarrhoea in Indian children: a randomised controlled trial. Journal of Clinical Gastroenterology 2007, 41(8):756-760.
58. Basu S., Chatterjee M., Ganguly S., Chandra P.K. Efficacy of Lactobacillus rhamnosus GG in acute watery diarrhoea of Indian children: a randomised controlled trial. Journal of Paediatric Child Health 2007, 43:837-842.
59. Canani B.R., Cirillo P., Terrin G., et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ 2007, 335:340.
60. Figueiredo P.P., Vieira E.C., Nicoli J.R., et al. Influence of oral inoculation with plasmid-free human Escherichia coli on the frequency of diarrhea during the first year of life in human newborns. Journal of Pediatric Gastroenterology Nutrition 2001, 33(1):70-74.
61. Isolauri E., Juntunen M., Rautanen T., et al. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991, 88(1):90-97.
62. Rosenfeldt V., Michaelsen K.F., Jakobsen M., et al. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatric Infectious Disease Journal 2002, 21:411-416.
63. Pedone C.A., Bernabeu A.O., Postaire E.R., et al. The effect of supplementation with milk fermented by Lactobacillus casei DN-114 001, on acute diarrhoea in children attending day care centres. International Journal of Clinical Practice 1999, 53:179-184.
64. Pedone C.A., Arnaud C.C., Postaire E.R., et al. Multicenter study on 928 children attending day care centers to evaluate the effect of milk fermented by Lactobacillus casei DN-114 001 on the incidence of diarrhoea. International Journal of Clinical Practice 2000, 54:568-571.
65. Hatakka K., Savilahti E., Ponka A., et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001, 322:1327.
66. Weizman Z., Asli G., Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005, 115:5-9.
67. Chouraqui J.P., Van Egroo L.D., Fichot M.C. Acidified milk fromula supplemented with bifidobacterium lactis: impact on infant diarrhea in residential care settings. Journal of Pediatric Gastroenterology Nutrition 2004, 38(3):288-292.
68. Oberhelman R.A., Gilman R.H., Sheen P., et al. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. Journal of Pediatrics 1999, 134:15-20.
69. Pereg D., Kimhi O., Tirosh A., et al. The effect of fermented yogurt on the prevention of diarrhea in a healthy adult population. American Journal of Infection Control 2005, 33:122-125.
70. Szajewska H., Mrukowicz J.Z. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. Journal of Pediatric Gastroenterology Nutrition 2005, 33:S17-S25.
71. Black, F. T., Andersen, P. L., Orskov, J. et al. (1989). Prophylactic efficacy of lactobacilli on travelers' diarrhea. In: Steffen, R. (ed.) Travel medicine. Conference on international travel medicine 1, Zurich, Switzerland. Berlin: Springer, 333-335.
72. Hilton E., Kolakowski P., Smith M., Singer C. Efficacy of Lactobacillus GG as a diarrhoea preventive. Journal of Travel Medicine 1997, 4:3-7.
73. Oksanen P.J., Salminen S., Saxelin M., et al. Prevention of travelers' diarrhoea by Lactobacillus GG. Annals of Medicine 1990, 22:53-56.
74. Kollaritsch H., Holst H., Grobara P., Wiedermann G. Prevention of travelers' diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study. Fortschritte Der Medizin 1993, 111(9):152-156.
75. de dios Pozo-Olano, J., Warram, J. H., Gomez, R. G. & Cavazos, M. G. (1978). Effect of a lactobacilli preparation on travelers' diarrhea. A randomized, double blind clinical trial. 74, 829-830.
76. Katelaris P.H., Salam I., Farthing M.J.G. Lactobacilli to prevent travelers' diarrhea?. New England Journal of Medicine 1995, 333:1360-1361.
77. McFarland L.V. Meta-analysis of probiotics for the prevention of travelers' diarrhea. Travel Medicine Infectious Disease 2007, 5:97-105.
78. Armuzzi A., Cremonini F., Bartolozzi F., et al. The effects of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Alimentary Pharmacology & Therapeutic 2001, 15:163-169.
79. Arvola T., Laiho K., Torkkeli S., et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomised study. Pediatrics 1999, 104:E64.
80. Cremonini F., Di Caro S., Nista E.C., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhea. Alimentary Pharmacology & Therapeutic 2002, 16:1461-1467.
81. Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Alimentary Pharmacology & Therapeutic 2005, 21:583-590.
82. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology 2006, 101:812-822.
83. Katz J.A. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. Journal of Clinical Gastroenterology 2006, 40:249-255.
84. Szajewska H., Ruszczynski M., Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: A meta-analysis of randomized controlled trials. Journal of Pediatrics 2006, 149:367-372.
85. Hawrelak J.A., Whitten D.L., Myers S.P. Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion 2005, 72:51-56.
86. Duman D.G., Bor S., Ozutemiz O., et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. European Journal of Gastroenterol Hepatology 2005, 17:1357-1361.
87. Wenus C., Goll R., Loken E.B., et al. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. European Journal of Clinical Nutrition 2008, 62:299-301.
88. de Vrese M. Effects of probiotic bacteria on gastrointestinal symptoms, Helicobacter pylori activity and antibiotics-induced diarrhoea. Gastroenterology 2003, 124:A560.
89. Cindoruk M., Erkan G., Karakan T., et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007, 12:309-316.
90. Szymanski H., Armanska M., Kowalska-Duplaga K., Szajewska H. Bifidobacteria longum PL03, Lactobacillus rhamnosus KL53A, and Lactobacillus plantarum PL02 in the prevention of antibiotic-associated diarrhea in children: a randomized controlled pilot trial. Digestion 2008, 78:13-17.
91. Thomas M.R., Litin S.C., Osmon D.R., et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clinic Proceedings 2001, 76:883-889.
92. Kim M.N., Kim N., Lee S.H., et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008, 13:261-268.
93. Plummer S., Weaver M.A., Harris J.C., et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. International Microbiology 2004, 7:59-62.
94. Safdar N., Barigala R., Said A., McKinley L. Feasibility and tolerability of probiotics for prevention of antibiotic-associated diarrhoea in hospitalized US military veterans. Journal of Clinical Pharmacy and Therapeutics 2008, 33:663-668.
95. Stein G.Y., Nanim R., Karniel E., et al. Probiotics as prophylactic agents against antibiotic-associated diarrhea in hospitalized patients. Harefuah 2007, 146(7):520-522.
96. Sullivan A., Johansson A., Svenungsson B., Nord C.E. Effect of Lactobacillus F19 on the emergence of antibiotic-resistant microorganisms in the intestinal microflora. Journal of Antimicrobial Chemotherapy 2004, 54:791-797.
97. Tankanow R.M., Ross M.B., Ertel I.J., et al. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP 1990, 24(4):382-384.
98. Hickson, M., D'Souza, A. L., Muthu, N., et al. (2007). Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ, 335(7610).
99. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271(24):1913-1918.
100. Johnston B.C., Supina A.L., Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006, 175:377-383.
101. Dendukuri N., Costa V., McGegor M., Brophy J.M. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005, 173:167-170.
102. Tomoda T., Nakano Y., Kageyama T. Intestinal Candida overgrowth and Candida infection in patients with leukemia: effect of Bifidobacterium administration. Bifidobact 1988, 7:71-74.
103. Delia P., Sansotta G., Donato V., et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. American Journal of Gastroenterology 2002, 97:2150-2152.
104. Urbancsek H., Kazar T., Mezes I., Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. European Journal of Gastroenterology Hepatology 2001, 13:391-396.
105. Delia P., Sansotta G., Donato V., et al. Famularo G. Use of probiotics for prevention of radiation-induced diarrhea. World Journal of Gastroenterology 2007, 13:912-915.
106. Giralt J., Regadera J.P., Verges R., et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008, 71:1213-1219.
107. Wolf B.W., Wheeler K.B., Ataya D.G., Garleb K.A. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food and Chemical Toxicology 1998, 36:1085-1094.
108. Salminen M.K., Tynkkynen S., Rautelin H., et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, non-infectious diarrhea in HIV patients on antiviral therapy: a randomized, placebo-controlled, crossover study. HIV Clinical Trials 2004, 5(4):183-191.
109. Trois L., Cardoso E.M., Miura E. Use of probiotics in HIV-infected children: a randomized double-blind controlled study. Journal of Tropical Pediatrics 2008, 54(1):19-24.
110. Saint-Marc T., Blehaut H., Musial C., Touraine J. AIDS related diarrhea: a double-blind trial of Saccharomyces boulardii. Sem Hôsp Paris 1995, 71:735-741.
111. Vanderhoof J.A., Young R.J., Murray N., Kaufman S.S. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. Journal of Pediatric Gastroenterology Nutrition 1998, 27:155-160.
112. Gaon D., Garmendia C., Murrielo N.O., et al. Effect of Lactobacillus strains (L. casei and L. acidophilus strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina (B Aires). 2002, 62:159-163.
113. SiemenhoffM.L., Dunn S.R., Zollner G.P., et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in endstage kidney disease using freeze-dried Lactobacillus acidophilus. Mineral and Electrolyte Metabolism 1996, 22:92-96.
114. Attar A., Flourie B., Rambaud J.C., et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999, 117(4):794-797.
115. Stotzer P.O., Blomberg L., Conway P.L., et al. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD. Scandinavian Journal of Infectious Diseases 1996, 28:615-619.
116. de Vrese M., Kuhn C., Titze A., et al. Einfluß von Art und Viabilität von Laktobazillen in Sauermilchprodukten auf die Laktoseverdauung. Akt Ernähr 1997, 22:44.
117. Gaon D., Doweck Y., Gomez Zavaglia A., et al. Lactose digestion by milk fermented with Lactobacillus acidophilus and Lactobacillus casei of human origin. Medicina (B Aires) 1995, 55:237-242.
118. de Vrese M., Stegelmann A., Richter B., et al. Probiotics-compensation for lactase insufficiency. American Journal of Clinical Nutrition 2001, 73:361-364.
119. Labayen I., Martinez J.A. Probiotic bacteria and lactase deficiencies. Gastroenterol Hepatology 2003, 26:S64-S72.
120. Suhr M., de Vrese M., Barth C.A. Differenzierende Untersuchung der β-galactosidaseaktivität von Wirts- und Mikroflora nach Joghurtverzehr. Milchwissenschaft 1995, 50:629-633.
121. Shaw A.D., Davies G.J. Lactose Intolerance: Problems in Diagnosis and Treatment. Journal of Clinical Gastroenterology 1999, 28:208-216.
122. Caplan M.S., Miller-Catchpole R., Kaup S., et al. Bifidobacterial supplementation reduces the incidence of necrotising enterocolitis in a neonatal rat model. Gastroenterology 1999, 117:577-583.
123. Dieleman L.A., Goerres M.S., Arends A., et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003, 52:370-376.
124. Li Z., Yang S., Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. Hepatology 2003, 37:343-350.
125. Madsen K.L., Doyle J.S., Jewell L.D., et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999, 116:1107-1114.
126. Gionchetti P., Rizello F., Venturi A., Campieri M. Probiotics in infective diarrhea and inflammatory diseases. Journal of Gastroenterol Hepatology 2000, 15:489-493.
127. Faubion W.A., Sandborn W.J. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad. Gastroenterology 2000, 18:630-635.
128. Guandalini S. Use of Lactobacillus-GG in paediatric Crohn's disease. Digestive and Liver Disease 2002, 34:S63-S65.
129. Malin M., Suomalainen H., Saxelin M., Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Annals of Nutrition and Metabolism 1996, 40:137-145.
130. Rembecken B.J., Snelling A.M., Hawkey P.M., et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354:635-639.
131. Shanahan F. Probiotics and inflammatory disease: is there a scientific rational?. Inflammatory Bowel Diseases 2000, 6:107-115.
132. Chapman T.M., Plosker G.L., Figgitt D.P. Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases. Bio Drugs 2007, 21(1):61-63.
133. Fricu P., Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. European Journal of Gastroenterology Hepatology 2003, 15:313-315.
134. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
135. Gupta P., Andrew H., Kirschner B.S., Guandalini S. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. Journal of Pediatric Gastroenterology Nutrition 2000, 31:453-457.
136. Mach T. Clinical usefulness of probiotics in inflammatory bowel diseases. J Physiol Pharmacol 2006, 57(Suppl. 9):23-33.
137. Kruis W., Schütz E., Fric P., et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology & Therapeutic 1997, 11:853-858.
138. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
139. Henker J., Müller S., Laass M.W., et al. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Zeitschrift Fur Gastroenterologie 2008, 46(9):874-875.
140. Venturi A., Gionchetti P., Rizzello F., et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Alimentary Pharmacology & Therapeutic 1999, 13(8):1103-1108.
141. Ishikawa H., Akedo I., Umesaki Y., et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. Journal of the American College of Nutrition 2003, 22(1):56-63.
142. Cui H.H., Chen C.L., Wang J.D., et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World Journal of Gastroenterology 2004, 10(10):1521-1525.
143. Zocco M.A., dal Verme L.Z., Cremonini F., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology & Therapeutic 2006, 23(11):1567-1574.
144. Borody T.J., Warren E.F., Leis S., et al. Treatment of ulcerative colitis using fecal bacteriotherapy. Journal of Clinical Gastroenterology 2003, 37(1):42-47.
145. Kato K., Mizuno S., Umesaki Y., et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology & Therapeutic 2004, 20(10):1133-1141.
146. Bibiloni R., Fedorak R.N., Tannock G.W., et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. American Journal of Gastroenterology 2005, 100(7):1539-1546.
147. Plein K., Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with specific respect to chronic diarrhea-a pilot study. Zeitschrift Fur Gastroenterologie 1993, 31:129-134.
148. Guslandi M., Mezzi G., Sorghi M., Testoni P.A. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digestive Diseases and Sciences 2000, 45(7):1462-1464.
149. Malchow H.A. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?. Journal of Clinical Gastroenterology 1997, 25(4):653-658.
150. Schultz M., Timmer A., Herfarth H.H., et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterology 2004, 15(4):5.
151. Rolfe, V. E., Fortun, P. J., Hawkey, C. J., & Bath-Hextall, F. (2006). Probiotics for maintenance of remission in Crohn's disease Cd004826. Cochrane Database Syst. Review, 4.
152. Gosselink M.P., Schouten W.R., van Lieshout L.M., et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Diseases of the Colon & Rectum 2004, 47(6):876-884.
153. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124(5):1202-1209.
154. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
155. Kuzela L., Kascak M., Vavrecka A. Induction and maintenance of remission with non-pathogenic Escherichia coli in patients with pouchitis. American Journal of Gastroenterology 2001, 96(11):3218-3219.
156. Laake K.O., Bjørneklett A., Aamodt G., et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scandinavian Journal of Gastroenterology 2005, 40(1):43-51.
157. Kuisma J., Mentula S., Jarvinen H., et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Alimentary Pharmacology & Therapeutic 2003, 17(4):509-515.
158. Tromm A., Niewerth U., Khoury M., et al. The probiotic E. coli strain Nissle 1917 for treatment of collagenous colitis: first results of an open-label trial. Zeitschrift Fur Gastroenterologie 2004, 42:365-369.
159. Wildt S., Munck L.K., Vinter-Jensen L., et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp lactis. Inflammatory Bowel Diseases 2006, 12:395-401.
160. Fanigliulo L., Comparato G., Aragona G., et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomedicine 2006, 77:85-89.
161. Nobaek S., Johansson M.L., Molin G., et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. American Journal of Gastroenterology 2000, 95(5):1231-1238.
162. Halpern G.M., Prindiville T., Blankenburg M., et al. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. American Journal of Gastroenterology 1996, 91(8):1579-1585.
163. Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299 V in patients with irritable bowel syndrome. European Journal of Gastroenterology Hepatology 2001, 13(10):1143-1147.
164. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128(3):541-551.
165. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. American Journal of Gastroenterology 2006, 101:1581-1590.
166. Sen S., Mullan M.M., Parker T.J., et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Digestive Diseases and Sciences 2002, 47(11):2615-2620.
167. O'Sullivan M.A., O'Morain C.A. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Digestive and Liver Disease 2000, 32:294-301.
168. Kim H.J., Camilleri M., McKinzie S., et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutic 2003, 17(7):895-904.
169. Hamilton-Miller, J. M. T. (2001). Probiotics in the management of irritable bowel syndrome: a review of clinical trials 212-216(5). Microbial Ecology in Health and Disease, 13(4).
170. Kolida S., Tuohy K., Gibson G.R. Prebiotic effects of inulin and
171. Bielecka M., Biedrzycka E., Majkowska A. Selection of probiotics and prebiotics for synbiotics and confirmation of their in vivo effectiveness. Food Research International 2002, 35:139-144.
172. Fooks L.J., Gibson G.R. In vitro investigations of the effect of probiotics and prebiotics on selected human intestinal pathogens. FEMS Microbiology Ecology 2002, 39:67-75.
173. Asahara T., Nomoto K., Shimizu K., et al. Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides. Journal of Applied Microbiology 2001, 91:985-996.
174. Bomba A., Nemcova R., Gancarcikova S., et al. Improvement of the probiotic effect of microorganisms by their combination with maltodextrins, fructo-oligosaccharides and polyunsaturated fatty acids. British Journal of Nutrition 2002, 88:S95-S99.
175. Langlands S.J., Hopkins M.J., Coleman N., Cummings J.H. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 2004, 53(11):1610-1616.
176. Cummings J.H., Macfarlane G. Gastrointestinal effects of prebiotics. British Journal of Nutrition 2002, 87:S145-S151.
177. Videla S., Vilaseca J., Antolin M., et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. American Journal of Gastroenterology 2001, 96:1486-1493.
178. Lewis S., Burmeister S., Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea. A randomized, controlled study. Clinical Gastroenterol Hepatology 2005, 3(5):442-448.
179. Kanamori Y., Sugiyama M., Hashizume K., et al. Experience of long-term synbiotic therapy in seven short bowel patients with refractory enterocolitis. Journal of Pediatric Surgery 2004, 39(11):1686-1692.
180. Cummings J.H., Christie S., Cole T.J. A study of fructo oligosaccharides in the prevention of travelers' diarrhoea. Alimentary Pharmacology & Therapeutic 2001, 15:1139-1145.
181. Brunser O., Gotteland M., Cruchet S., et al. Effect of a milk formula with prebiotics on the intestinal microbiota of infants after an antibiotic treatment. Pediatric Research 2006, 59:451-456.
182. Lewis S., Burmeister S., Cohen S., et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Alimentary Pharmacology & Therapeutic 2005, 21:469-477.
183. Duggan C., Penny M.E., Hibberd P., et al. Oligofructose-supplemented infant cereal: 2 randomized, blinded, community-based trials in Peruvian infants. American Journal of Clinical Nutrition 2003, 77:937-942.
184. Hunter J.O., Tuffnell Q., Lee A.J. Controlled trial of oligofructose in the management of irritable bowel syndrome. Journal of Nutrition 1999, 129:1451S-1453S.
185. Mountzouris K.C., McCartney A.L., Gibson G.R. Intestinal microflora of human infants and current trends for its nutritional modulation. British Journal of Nutrition 2002, 87:405-420.
186. Vandenplas Y. Oligosaccharides in infant formula. British Journal of Nutrition 2002, 87:S293-S296.
187. Agarwal R., Sharma N., Chaudhry R., et al. Effects of oral Lactobacillus GG on enteric microflora in low-birth-weight neonates. Journal of Pediatric Gastroenterology Nutrition 2003, 36:397-402.
188. Millar M.R., Bacon C., Smith S.L., et al. Enteral feeding of premature infants with Lactobacillus GG. Archives of Disease in Childhood 1993, 69:483-487.
189. Boehm G., Casetta P., Lidestri M., et al. Effect of dietary oligosaccharides (OS) on faecal bifidobacteria in formula-fed preterm infants. Journal of Pediatric Gastroenterology Nutrition 2001, 32:393.
190. Moro G., Minoli I., Mosca F., et al. Dosage-related bifidogenic effects of galacto- and fructo-oligosaccharides in formula-fed term infants. Journal of Pediatric Gastroenterology Nutrition 2002, 34:291-295.
191. Knol J., Boehm G., Lidestri M., et al. Increase of faecal bifidobacteria due to dietary oligosaccharides induces a reduction of clinically relevant pathogen germs in the faeces of formula-fed preterm infants. Acta Paediatrica Suppl 2005, 94(449):31-33.
192. Knol J., Scholtens P., Kafka C., et al. Colon microflora in infants fed formula with galacto- and fructo-oligosaccharides: more like breast-fed infants. Journal of Pediatric Gastroenterology Nutrition 2005, 40(1):36-42.
193. Fanaro, S., Boehm, G., Garssen, J. et al. Galacto-oligosaccharides and long-chain fructo-oligosaccharides as prebiotics in infant formulas: a review. Acta Paediatr Suppl, 94 (449), 22-26.
194. Danan C., Huret Y., Tessèdre A-C., et al. Could oligosaccharide supplementation promote gut colonization with a beneficial flora in preterm infants?. Journal of Pediatric Gastroenterology Nutrition 2000, 30:217-219.
195. Butel M-J., Waligora-Dupriet A-J., Szylit O. Prebiotics and experimental model of neonatal necrotising enterocolitis. British Journal of Nutrition 2002, 87:S213-S219.
196. Juffrie M. Fructo-oligosaccharides and diarrhea. Bioscience Microflora 2002, 21:31-34.
197. Saavedra J., Tschernia A. Human studies with probiotics and prebiotics: clinical implications. British Journal of Nutrition 2002, 87:S241-S246.
198. Waligora-Dupriet A.J., Campeotto F., Nicolis I., et al. Effect of oligofructose supplementation on gut microflora and well-being in young children attending day care centre. International Journal of Food Microbiology 2007, 113:108-113.
199. Fisberg, M., Maulen, I., Vasquez, E., et al. (2000). Effect of oral supplementation with and without synbiotics on catch-up growth in preschool children Abstract 987. Journal of Pediatric Gastroenterology Nutrition, 31.
200. Firmansyah, A., Pramita, G. D., Carrié Fässler, A. L., et al. (2000). Improved humoral immune response to measles vaccine in infants receiving infant cereals with fructo-oligosaccharides Abstract 521. Journal of Pediatric Gastroenterology Nutrition, 31.
201. Nopchinda S., Varavithya W., Phuapradit P., et al. Effect of Bifidobacterium Bb12 with or without Streptococcus thermophilus supplemented formula on nutritional status. Journal of the Medical Association of Thailand 2002, 85:S1225-S1231.